IA
KRYS icon

IFP Advisors’s Krystal Biotech KRYS Stock Holding History

IFP Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.4K Sell
55
-10
-15% -$2.99K ﹤0.01% 2965
2026
Q1 		$16.8K Sell
65
-200
-75% -$53.2K ﹤0.01% 2865
2025
Q4 		$65.3K Buy
265
+189
+249% +$39.8K ﹤0.01% 2038
2025
Q3 		$13.4K Buy
76
+66
+660% +$9.88K ﹤0.01% 2761
2025
Q2 		$1.37K Buy
+10
New +$1.47K ﹤0.01% 4074
2024
Q2 		– Sell
-267
Closed -$47.3K – 3288
2024
Q1 		$47.3K Buy
267
+7
+3% +$972 ﹤0.01% 1614
2023
Q4 		$32.2K Buy
260
+229
+739% +$25.4K ﹤0.01% 1730
2023
Q3 		$3.6K Buy
+31
New +$3.78K ﹤0.01% 2637

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

IFP Advisors's KRYS Position: Q2 2026 in Review

IFP Advisors reduced its Krystal Biotech (KRYS) stake by 15% in Q2 2026, selling an estimated $2.99K and leaving 55 shares worth $20.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2965.

IFP Advisors first reported a position in KRYS in Q3 2023 and has held it in 8 quarters since. The position peaked at $65.3K in Q4 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • IFP Advisors held 55 shares of Krystal Biotech worth $20.4K as of Q2 2026.
  • IFP Advisors sold 10 Krystal Biotech shares in Q2 2026, an estimated $2.99K.
  • Krystal Biotech made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2965 holding.
  • IFP Advisors first reported a position in Krystal Biotech in Q3 2023 and has held it in 8 quarters since.
  • IFP Advisors's Krystal Biotech position peaked at $65.3K in Q4 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.